Skip to search formSkip to main contentSkip to account menu

ECOG Performance Status 1

Known as: ECOG 1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
INTRODUCTION: Meta-analyses have shown concurrent chemoradiotherapy (CCRT) provides no survival benefit over radiotherapy in… 
2018
2018
618Background: Tivozanib is a VEGFR-TKI with high specificity and lower incidence of class effect adverse events. As combinations… 
Review
2016
Review
2016
Background Administration of paclitaxel is associated with an increased survival rate in ovarian cancer patients. Despite the… 
2012
2012
2552 Background: Eribulin mesylate is a microtubule dynamics inhibitor approved by FDA for patients (pts) with metastatic breast… 
2012
2012
627 Background: Optimal treatment strategies in frail and/or elderly patients with metastatic colorectal cancer have not been… 
2011
2011
4501 Background: "Intracrine" androgen signaling is linked to castrate-resistant prostate cancer (CRPC) and a "credentialed… 
2009
2009
5048 Background: AA is a potent blocker of CYP17, required for synthesis of testosterone in the testes, adrenals, and prostate… 
2004
2004
2001 Background: Aberrant VEGFR expression in breast tumor cells and EGFR expression in endothelial cells may contribute to tumor… 
2002
2002
PURPOSE The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung…